Low Expression of Circular RNA hsa_circ_0078607 Predicts Poor Prognosis in High-Grade Serous Ovarian Cancer

Figures & data

Table 1 The Baseline Information of High-Grade Serous Ovarian Cancer Patients (HGSOC) (N=49)

Characteristics	Numbers of Cases (%)
Age (years)
<60	24(48.97)
≥60	25(51.03)
FIGO stage
I	3(6.12)
II	7(14.28)
III	33(67.35)
IV	6(12.25)
Tumor size (cm)
< 10	36(73.47)
≥10	13(26.53)
Ascites (mL)
<1000	27(55.10)
≥1000	22(44.90)
Serum CA125 (ng/mL)
<500	22(44.89)
≥500	27(55.11)
Vital status
Living	18(36.73)
Deceased	31(63.27)
Sensitivity to chemotherapy
Platinum sensitive	35(71.43)
Platinum resistance	14(28.57)
circ_0078607
Low	31(63.27)
High	18(36.73)

Figure 1 Expression of circ_0078607 in HGSOC and its correlation with prognosis. (A) Relative expression of circ_0078607 in 49 pairs of HGSOC tissues and their corresponding adjacent non-cancerous tissues. (B) Correlation between circ_0078607 expression and PFS in HGSOC. (C) Correlation between circ_0078607 expression and OS in HGSOC. ***p < 0.001.

Table 2 Correlations Between circ_0078607 Expression and Clinical Features in HGSOC Patients

Parameter	Variable	circ-0078607 Expression				P value
		Low	%	High	%
Age (years)	<60	14	(28.57)	10	(20.41)	0.483
	≥60	17	(34.69)	8	(16.33)
FIGO stage	I–II	3	(6.12)	7	(14.28)	0.014
	III–IV	28	(57.14)	11	(22.45)
Tumor size (cm)	< 10	22	(44.89)	14	(28.57)	0.603
	≥10	9	(18.38)	4	(8.16)
Ascites (mL)	<1000	14	(28.57)	13	(26.53)	0.066
	≥1000	17	(34.70)	5	(10.20)
Serum CA125 (ng/mL)	<500	10	(20.41)	12	(24.49)	0.019
	≥500	21	(42.86)	6	(12.24)
Sensitivity to chemotherapy	Platinum sensitive	20	(40.82)	15	(30.61)	0.159
	Platinum resistance	11	(22.45)	3	(6.12)
Vital status	Living	8	(16.33)	10	(20.4)	0.037
	Deceased	23	(46.94)	8	(16.33)

Table 3 Univariate and Multivariate Cox Analysis of Progression-Free Survival (PFS) in HGSOC

Variable	Univariate Analysis			Multivariate Analysis
	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
Age	1.274	0.741–2.315	0.377	0.913	0.457–1.826	0.798
FIGO stage	2.629	1.618–5.199	0.002	3.112	1.563–6.196	0.011
Ascites	2.421	1.297–5.473	0.011	1.589	0.635–3.978	0.322
Tumor size	0.831	0.432–1.559	0.568	0.952	0.415–2.184	0.907
Serum CA125	2.025	1.337–4.268	0.007	2.672	1.198–5.958	0.036
circ_0078607	2.083	1.392–4.327	0.005	2.180	1.109–4.284	0.024

Table 4 Univariate and Multivariate Cox Analysis of Overall Survival (OS) in HGSOC

Variable	Univariate Analysis			Multivariate Analysis
	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
Age	1.493	0.749–3.148	0.257	1.144	0.510–2.567	0.744
FIGO stage	4.586	1.235–6.418	0.018	2.149	1.562–4.111	0.028
Ascites	1.536	0.731–3.229	0.219	2.002	0.711–5.636	0.189
Tumor size	0.968	0.447–2.087	0.932	1.428	0.522–3.911	0.488
Serum CA125	1.893	0.978–4.072	0.065	1.666	0.696–3.911	0.252
circ_0078607	2.187	1.047–4.338	0.043	1.795	1.043–3.374	0.038